To include your compound in the COVID-19 Resource Center, submit it here.

CTII's cell therapy for diabetes

By BC Staff | Aug 16, 1993 | 7:00 AM GMT

Noteworthy

CTII's cell therapy for diabetes

CytoTherapeutics Inc. was to announce today that it has begun Phase I trials of polymer-encapsulated islet cells that will be implanted in patients with Type I insulin-dependent diabetes and Type II diabetes, as well as in healthy volunteers.

The study is being conducted under an investigator-sponsored IND and CTII anticipates announcing results at a scientific forum at the end of the year.

The polymer membrane surrounding the

Read the full 728 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE